Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2014-09-04 Major Shareholding Noti…
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Change in substantial holding from BTT 16 pages 227.6KB
Major Shareholding Notification Classification · 100% confidence The document is a Notice of Change of Interests of Substantial Holder filed under section 671B of the Corporations Act 2001 (Cth). It includes detailed information about changes in voting power and shareholdings of substantial holders in Mayne Pharma Group Limited, including transaction history and associations. The form referenced is Form 604, which is a regulatory filing used to notify changes in substantial shareholdings. This type of document is a regulatory announcement about share ownership changes and does not constitute a financial report, earnings release, or other report types. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and detail support a high confidence in this classification.
2014-09-04 English
2014 Appendix 4E & Annual Report 84 pages 2.9MB
Annual Report Classification · 100% confidence The document is dated 27 August 2014 and is titled 'Full Year Results – Financial Year Ended 30 June 2014' for Mayne Pharma Group. It includes an Appendix 4E and an Annual Report. The text contains detailed financial data, including revenue, profit, earnings per share, and a comprehensive table of financial statements and notes. It also includes a Chairman's letter, business overview, growth strategy, and detailed financial summaries. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The presence of detailed financial statements, notes, auditor's report, and management commentary confirms this is the official yearly report covering company activity and full financial performance for the fiscal year ended 30 June 2014. Therefore, the document fits the definition of an Annual Report (10-K equivalent). FY 2014
2014-08-26 English
2014 Full Year Results Media Release 6 pages 248.2KB
Annual Report Classification · 95% confidence The document is an ASX announcement dated 27 August 2014 reporting the consolidated financial results for the fiscal year ended 30 June 2014. It includes detailed financial performance metrics such as revenue, gross profit, EBITDA, net profit after tax, segment performance, cash flow, pipeline updates, and outlook. The document is comprehensive and contains substantive financial data and analysis for the full fiscal year (FY14). It is not merely an announcement of a report or a certification but a full financial results disclosure. The content aligns with the characteristics of an Annual Report or a full year financial results report. Given the detailed financial data and the fiscal year coverage, the appropriate classification is Annual Report (10-K). FY 2014
2014-08-26 English
2014 Full Year Results Investor Presentation 20 pages 1.5MB
Earnings Release Classification · 95% confidence The document is titled 'FY14 Results Presentation' and dated 27 August 2014, indicating it is a presentation of the full fiscal year 2014 financial results. It contains detailed financial data including revenue, gross profit, EBITDA, NPAT, segment breakdowns, operational highlights, and balance sheet information. The content is comprehensive and includes forward-looking statements, non-IFRS financial measures, and detailed segment analysis, typical of an earnings presentation. The document is about 15,000 characters long, which is substantial and contains actual financial data and analysis rather than just an announcement or summary. This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights. It is not a full Annual Report (10-K) as it lacks the full audited financial statements and extensive disclosures typical of such reports, nor is it a Management Discussion & Analysis (MDA) which is more narrative and detailed. It is also not an Investor Presentation (IP) as it focuses primarily on financial results rather than strategy or market positioning. Therefore, the best classification is Earnings Release (ER). FY 2014
2014-08-26 English
2014 Corporate Governance Statement 15 pages 601.5KB
Governance Information Classification · 95% confidence The document is titled 'CORPORATE GOVERNANCE STATEMENT' and extensively discusses the company's governance practices, board responsibilities, committee structures, director independence, and related governance policies. It references compliance with ASX Corporate Governance Council Principles and Recommendations and details the Board's role, composition, and committees such as the Audit Committee. There is no indication that this is an announcement or a brief summary; rather, it is a detailed governance report. This aligns with the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length (15,000 characters) and content confirm it is a substantive governance report, not a mere announcement or certification. Therefore, the appropriate classification is CGR with high confidence.
2014-08-26 English
Mayne Pharma appoints new Board member 1 page 215.2
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 26 August 2014 about the appointment of a new board member, Professor Bruce G Robinson, to Mayne Pharma Group Limited. It details his background, qualifications, and the fact that his appointment will be voted on at the upcoming AGM. There is no financial data, no report attached or referenced as being published, and the document is relatively short (2768 characters). The content clearly relates to a change in the company's board of directors. Therefore, the appropriate classification is Board/Management Information (MANG).
2014-08-25 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.